Tiziana Larussa Selected Research

CT-P13

2/2022	Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
7/2019	Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tiziana Larussa Research Topics

Disease

16	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023 - 04/2012
10	Ulcerative Colitis 02/2022 - 10/2010
4	Crohn Disease (Crohn's Disease) 02/2022 - 08/2019
3	Inflammation (Inflammations) 01/2022 - 03/2019
3	Infections 07/2021 - 08/2014
3	Peptic Ulcer (Peptic Ulcers) 01/2021 - 08/2018
2	Gastritis 01/2021 - 10/2010
2	Non-alcoholic Fatty Liver Disease 01/2021 - 12/2020
2	Metabolic Bone Diseases (Osteopenia) 08/2019 - 04/2012
2	Celiac Disease (Celiac Sprue) 01/2017 - 04/2012
1	Iron Deficiencies 01/2022
1	Iron-Deficiency Anemia (Anemia, Iron Deficiency) 01/2022
1	Gastrointestinal Diseases (Functional Gastrointestinal Disorders) 01/2022
1	Anemia 01/2022
1	Hypertension (High Blood Pressure) 01/2021
1	Insulin Resistance 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Obesity 01/2021
1	Colitis 09/2020
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2019
1	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 02/2019
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 06/2017
1	Dysbiosis 04/2015
1	Gastroesophageal Reflux (GERD) 04/2015
1	Osteoporosis 04/2012
1	Pain (Aches) 10/2010

Drug/Important Bio-Agent (IBA)

4	Adalimumab (Humira)FDA Link 01/2023 - 08/2018
4	Biosimilar PharmaceuticalsIBA 01/2023 - 07/2019
3	Infliximab (Remicade)FDA Link 02/2022 - 07/2019
2	CT-P13IBA 02/2022 - 07/2019
2	golimumab FDA Link 12/2021 - 09/2017
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 09/2020
2	AntioxidantsIBA 01/2021 - 03/2019
2	CytokinesIBA 11/2019 - 10/2019
2	Virulence Factors (Pathogenicity Factors)IBA 11/2019 - 08/2018
2	Adrenal Cortex Hormones (Corticosteroids)IBA 03/2019 - 04/2017
1	GP2017IBA 01/2023
1	IronIBA 01/2022
1	SteroidsIBA 01/2021
1	PolyphenolsIBA 01/2021
1	PhytochemicalsIBA 01/2021
1	ResveratrolIBA 09/2020
1	4-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA 07/2020
1	Interleukin-33IBA 11/2019
1	Chemokine ReceptorsIBA 10/2019
1	Vitamin D FDA LinkGeneric 10/2019
1	ChemokinesIBA 10/2019
1	vedolizumabIBA 08/2019
1	Immunologic Factors (Immunomodulators)IBA 03/2019
1	Toll-Like Receptors (Toll-Like Receptor)IBA 06/2017
1	Toll-Like Receptor 2IBA 06/2017
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 04/2017
1	oleuropeinIBA 04/2017
1	Interleukin-17 (Interleukin 17)IBA 04/2017
1	Azathioprine (Imuran)FDA LinkGeneric 04/2017
1	Pantoprazole (Protonix)FDA LinkGeneric 04/2015
1	Proton Pump InhibitorsIBA 04/2015
1	Urea (Carbamide)FDA LinkGeneric 08/2014
1	OsteoprotegerinIBA 04/2012
1	AutoantibodiesIBA 04/2012
1	SmokeIBA 04/2012
1	thiopurine methyltransferase (thiopurine S-methyltransferase)IBA 04/2012
1	Immunosuppressive Agents (Immunosuppressants)IBA 10/2010
1	Lansoprazole (Prevacid)FDA LinkGeneric 10/2010
1	Mesalamine (Mesalazine)FDA LinkGeneric 10/2010
1	Celecoxib (Celebrex)FDA Link 10/2010

Therapy/Procedure

5	Therapeutics 01/2022 - 10/2010
1	Intravenous Administration 01/2022
1	Biological Therapy 07/2021
1	Mediterranean Diet 12/2020
1	Diet Therapy (Therapy, Diet) 08/2019
1	Complementary Therapies (Alternative Medicine) 02/2019
1	Gluten-Free Diet 01/2017